Impact of prior lines of systemic therapy (PST) on the efficacy of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC)

D Rischin, NI Khushalani, CD Schmults, A Guminski, ALS Chang, KD Lewis, AM Lim, L Hernandez-Aya, BGM Hughes, D Schadendorf, A Hauschild, E Stankevich, J Booth, S Li, Z Chen, J Desai, I Lowy, MG Fury, MR Migden